Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Receivables (2016 - 2025)

Nutex Health's Receivables history spans 16 years, with the latest figure at $319.4 million for Q4 2025.

  • For Q4 2025, Receivables rose 8768.41% year-over-year to $319.4 million; the TTM value through Dec 2025 reached $319.4 million, up 8768.41%, while the annual FY2025 figure was $319.4 million, 8768.41% up from the prior year.
  • Receivables for Q4 2025 was $319.4 million at Nutex Health, up from $7.3 million in the prior quarter.
  • Across five years, Receivables topped out at $319.4 million in Q4 2025 and bottomed at $334958.0 in Q2 2021.
  • The 5-year median for Receivables is $7.2 million (2021), against an average of $54.7 million.
  • The largest annual shift saw Receivables skyrocketed 28525.17% in 2022 before it plummeted 93.85% in 2024.
  • A 5-year view of Receivables shows it stood at $3.3 million in 2021, then surged by 1677.81% to $58.3 million in 2022, then grew by 0.45% to $58.6 million in 2023, then tumbled by 93.85% to $3.6 million in 2024, then soared by 8768.41% to $319.4 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Receivables are $319.4 million (Q4 2025), $7.3 million (Q3 2025), and $5.7 million (Q2 2025).